Skip to main content
. Author manuscript; available in PMC: 2022 Feb 7.
Published in final edited form as: Gynecol Oncol. 2020 Oct 31;160(1):302–311. doi: 10.1016/j.ygyno.2020.10.010

Fig. 2.

Fig. 2.

Mebendazole’s inhibitory effects on ovarian cancer cells; (A) MTT assay results of 48 or 72 h mebendazole treatment of MESOV, ES2, A2780, SKOV3 null p53, SKOV3 R248W p53 and SKOV3 R273H p53 cells. (B) Colony formation assay in MES-OV (R282W p53), A2780 (WT) and SKOV3 (p53 null) cells treated with mebendazole for 8 h. Cell colonies were counted after staining with 0.5% crystal violet dye. * p ≤ 0.05.